Skip to main content

Table 3 Multivariable Fine and Gray models of time to events

From: Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients

 

Virologic Failure or Other Discontinuation

Virologic Failure

Discontinuation due to Virologic Failure

Other Discontinuation

Virologic Suppression

aHR (95% CI)

p

aHR (95% CI)

p

aHR (95% CI)

p

aHR (95% CI)

p

aHR (95% CI)

p

DRV/RIT

0.76 (0.56,1.03)

0.08

0.50 (0.28,0.91)

0.02

0.00 (0.00,0.00)

<.0001

0.93 (0.65,1.33)

0.68

0.99 (0.82,1.21)

0.96

FTC/TEN

1.02 (0.86,1.21)

0.84

1.30 (0.99,1.70)

0.06

1.41 (0.87,2.28)

0.16

0.87 (0.70,1.08)

0.20

0.99 (0.87,1.12)

0.82

Age (per 10y)

0.89 (0.83,0.95)

<.001

1.02 (0.91,1.15)

0.70

0.89 (0.73,1.09)

0.27

0.86 (0.79,0.94)

<.001

1.04 (0.98,1.10)

0.17

Gender & MSM

 Female

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

 MSM

0.68 (0.55,0.84)

<.001

0.73 (0.51,1.03)

0.08

0.46 (0.24,0.89)

0.02

0.79 (0.61,1.03)

0.08

1.20 (1.00,1.45)

0.05

 Male, not MSM

0.72 (0.59,0.88)

<.01

0.90 (0.64,1.25)

0.51

0.70 (0.42,1.17)

0.17

0.76 (0.59,0.98)

0.03

1.06 (0.87,1.28)

0.57

 Missing

0.74 (0.56,0.98)

0.03

0.80 (0.47,1.35)

0.40

0.64 (0.27,1.55)

0.33

0.83 (0.60,1.15)

0.26

1.13 (0.90,1.42)

0.31

Race

White

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Black

0.89 (0.64,1.23)

0.47

1.41 (0.88,2.26)

0.15

1.18 (0.47,2.95)

0.72

0.64 (0.40,1.04)

0.07

1.16 (0.88,1.54)

0.29

Aboriginal Peoples

1.39 (1.05,1.85)

0.02

1.14 (0.72,1.82)

0.57

1.46 (0.71,2.99)

0.30

1.32 (0.91,1.89)

0.14

0.68 (0.51,0.92)

0.01

Other

0.89 (0.67,1.18)

0.42

1.04 (0.68,1.59)

0.86

0.79 (0.36,1.75)

0.56

0.82 (0.56,1.19)

0.29

1.15 (0.94,1.40)

0.17

Missing

1.17 (0.98,1.39)

0.08

0.75 (0.55,1.01)

0.06

0.70 (0.43,1.14)

0.15

1.38 (1.12,1.72)

<.01

0.93 (0.80,1.08)

0.35

IDU

 No

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

 Yes

1.68 (1.39,2.02)

<.0001

1.46 (1.05,2.04)

0.03

1.64 (0.92,2.94)

0.09

1.50 (1.20,1.88)

<.001

0.69 (0.58,0.82)

<.0001

 Missing

1.11 (0.83,1.49)

0.48

1.16 (0.68,1.96)

0.58

1.10 (0.41,2.93)

0.85

1.04 (0.74,1.45)

0.83

0.91 (0.72,1.14)

0.40

Province

 BC

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

 ON

0.95 (0.77,1.16)

0.60

1.11 (0.81,1.54)

0.52

0.67 (0.34,1.31)

0.24

0.90 (0.69,1.17)

0.44

0.97 (0.82,1.15)

0.73

 QC

0.82 (0.66,1.02)

0.08

1.26 (0.88,1.80)

0.21

1.03 (0.51,2.08)

0.93

0.68 (0.51,0.90)

<.01

1.02 (0.86,1.21)

0.83

Baseline CD4 (per 100)

  < 200

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

 200–349

0.83 (0.71,0.96)

0.01

0.93 (0.73,1.20)

0.58

1.16 (0.76,1.77)

0.48

0.84 (0.69,1.02)

0.08

1.18 (1.04,1.33)

<.01

 350–499

0.80 (0.63,1.01)

0.06

0.52 (0.33,0.84)

<.01

0.60 (0.23,1.56)

0.29

1.00 (0.76,1.31)

0.99

1.35 (1.14,1.61)

<.001

  ≥ 500

1.07 (0.80,1.45)

0.64

0.79 (0.44,1.42)

0.44

0.95 (0.33,2.69)

0.92

1.22 (0.87,1.71)

0.25

1.36 (1.08,1.71)

<.01

 Baseline VL ≥ 100,000

1.20 (1.05,1.38)

<.01

1.74 (1.38,2.20)

<.0001

2.27 (1.49,3.48)

<.001

0.95 (0.80,1.13)

0.57

0.61 (0.55,0.68)

<.0001

Calendar Year

 2003–2006

Ref.

 

Ref.

 

Ref.

 

Ref.

 

Ref.

 

 2007–2009

0.96 (0.79,1.17)

0.69

0.68 (0.50,0.92)

0.01

0.41 (0.24,0.71)

<.01

1.11 (0.87,1.42)

0.39

0.96 (0.82,1.12)

0.58

 2010–2012

1.12 (0.88,1.42)

0.35

0.88 (0.61,1.28)

0.50

0.64 (0.33,1.24)

0.19

1.03 (0.77,1.38)

0.84

0.67 (0.56,0.81)

<.0001

  1. AHR adjusted hazard ratio, DRV/r darunavir/ritonavir, ATZ/r atazanavir/ritonavir, FTC emtricitabine, TDF tenofovir, NRTI nucleoside reverse transcriptase inhibitor, MSM men who have sex with men, VL viral load
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us